GlassScriptPhysician profile
Deanne Garay
NPI 1417356387
$5,093.80
in general payments reported to CMS, 2019-2025
21 companies · $786 in 2025
The $786 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.47 · 2022: $2,424 · 2023: $1,371 · 2024: $440 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $597.63 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $537.56 | 2022-2025 | Trintellix |
| Corium, LLC | $505.58 | 2021-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $499.59 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $470.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $435.71 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $383.54 | 2022-2025 | Invega Sustenna, Spravato |
| Ironshore Pharmaceuticals INC. | $283.71 | 2022-2023 | Jornay Pm |
| Abbvie INC. | $280.67 | 2024-2025 | |
| Alkermes, INC. | $252.69 | 2022-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $236.12 | 2022-2023 | Adzenys Xr-Odt |
| Lundbeck LLC | $215.25 | 2022-2024 | Rexulti |
| Noven Therapeutics, LLC | $100.57 | 2022-2023 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $85.30 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $71.52 | 2025 | Fanapt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.55 | 2024 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $23.81 | 2024 | Austedo Xr |
| Indivior INC. | $20.60 | 2024 | Perseris |
| Acadia Pharmaceuticals INC | $20.59 | 2024 | Nuplazid |
| Validus Pharmaceuticals LLC | $17.20 | 2023 | Equetro |
| Idorsia Pharmaceuticals US INC | $16.78 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanne Garay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.